


PRODUCT INFORMATION



Alfuzosin-d₇ Item No. 34999

CAS Registry No.: 1133386-93-2
Formal Name: N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furan-2,3,3,4,4,5,5-d₇-carboxamide
Synonyms: SL 77499-10-d₇, Uroxatral-d₇
MF: C₁₉H₂₀D₇N₅O₄
FW: 396.5
Chemical Purity: ≥90% (Alfuzosin)
Deuterium Incorporation: ≥99% deuterated forms (d₁-d₇); ≤1% d₀
UV/Vis.: λ_{max}: 250 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Alfuzosin-d₇ is intended for use as an internal standard for the quantification of alfuzosin (Item No. 13648) by GC- or LC-MS. The accuracy of the sample weight in this vial is between 5% over and 2% under the amount shown on the vial. If better precision is required, the deuterated standard should be quantitated against a more precisely weighed unlabeled standard by constructing a standard curve of peak intensity ratios (deuterated versus unlabeled).

Alfuzosin-d₇ is supplied as a solid. A stock solution may be made by dissolving the alfuzosin-d₇ in the solvent of choice, which should be purged with an inert gas. Alfuzosin-d₇ is soluble in DMSO.

Description

Alfuzosin is an antagonist of α₁-adrenergic receptors (α₁-ARs; K_is = 10, 10, and 3.16 nM for α_{1A}-, α_{1B}-, and α_{1D}-ARs, respectively).¹ It increases the amount of phenylephrine needed to increase urethral and arterial blood pressure in pithed rats when administered at a dose of 10 mg/kg.² Formulations containing alfuzosin have been used in the treatment of benign prostatic hyperplasia.

References

1. Kenny, B.A., Miller, A.M., Williamson, I.J.R., *et al.* Evaluation of the pharmacological selectivity profile of α₁ adrenoceptor antagonists at prostatic α₁ adrenoceptors: Binding, functional and *in vivo* studies. *Br. J. Pharmacol.* **118**(4), 871-878 (1996).
2. Martin, D.J., Lluet, P., Pouyet, T., *et al.* Relationship between the effects of alfuzosin on rat urethral and blood pressures and its tissue concentrations. *Life Sci.* **63**(3), 169-176 (1998).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/08/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM